Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherCARDIOVASCULAR PHARMACOLOGY

Effect of Cyclopiazonic Acid on the Force-Frequency Relationship in Human Nonfailing  Myocardium

Robert H. G. Schwinger, Klara Brixius, Udo Bavendiek, Susanne Hoischen, Jochen Müller-Ehmsen, Birgit Bölck and Erland Erdmann
Journal of Pharmacology and Experimental Therapeutics October 1997, 283 (1) 286-292;
Robert H. G. Schwinger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klara Brixius
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Udo Bavendiek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanne Hoischen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jochen Müller-Ehmsen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Birgit Bölck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erland Erdmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The present study investigated the functional role of the sarcoplasmic reticulum Ca++-ATPase in contraction and relaxation, intracellular Ca++-transients, as well as on the force-frequency relationship in human myocardium. The Ca++-ATPase activity of membrane vesicles isolated from sarcoplasmic reticulum (SR) obtained from nonfailing donor hearts (n = 7) was measured in the presence of cyclopiazonic acid (CPA, 0–30 μM), a highly specific inhibitor of the Ca++-ATPase of the SR (SERCA). The effects of CPA on parameters of contraction and relaxation, force-frequency relationship and [Ca++]i transients (with fura-2) were studied on isolated left ventricular muscle strips from human nonfailing myocardium. CPA concentration-dependently inhibited SERCA activity of isolated SR vesicles. In the presence of CPA (30 μM) the former positive force-frequency relationship in human left ventricular nonfailing myocardium became negative. Especially at high frequencies of stimulation, CPA decreased developed tension, peak rate of tension rise and systolic fura-2-light emission, whereas time to peak tension, time to peak [Ca++]i, time to 95% relaxation, diastolic tension and diastolic Ca++ levels were increased. Peak rate of tension decay and time to half-relaxation and half-decay of [Ca++]i were not altered significantly after treatment with CPA. These findings provide evidence that the SERCA plays a functional role in the frequency-dependent increase in force of contraction in human myocardium. Because an impaired function of the SERCA is predominantly followed by alterations of inotropic and to a lesser degree of lusitropic function, other important factors to lower [Ca++]i and influence relaxation may be present in human myocardium to compensate for the reduced SERCA activity, e.g.,Na+-Ca++ exchanger.

Footnotes

  • Send reprint requests to: Dr.med. Robert H.G. Schwinger, Universität zu Köln, Medizinische Klinik III, Joseph-Stelzmannstr 9, D-50924 Köln, Germany.

  • ↵1 Experimental work was supported by grants from the Deutsche Forschungsgemeinschaft (to R.H.G.S.) (Schw), the Zentrum für Molekulare Medizin Köln (grant from the Bundesministeriums für Bildung, Wissenschaft, Forschung und Technologie 1 KS 9501 to R.H.G.S.) and the Graduiertenkolleg für Molekulare Medizin der Universität zu Köln (to R.H.G.S.). This work contains data of the Doctoral Thesis of U.B., S.H. and B.B. (University of Cologne, in preparation). Part of the study was presented at the spring meeting of the American College of Cardiology in New Orleans, Louisiana (19–22 March 1995).

  • Abbreviations:
    +T
    peak rate of tension rise
    −T
    peak rate of tension decay
    TPT
    time to peak tension
    T1/2T
    time to half relaxation
    T95T
    time to 95% relaxation
    SR
    sarcoplasmic reticulum
    SERCA
    SR-Ca++-ATPase
    CPA
    cyclopiazonic acid
    FFR
    force-frequency relationship
    I1/2I
    time at half decay of Ca++
    Isyst
    systolic light emission
    IPI
    time to peak Ca++
    Na2EDTA
    ethylenedinitrilotetraacetic acid disodium salt dihydrate
    AM
    acetoxymethyl
    EGTA
    ethyleneglycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid
    • Received July 8, 1996.
    • Accepted June 2, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 283, Issue 1
1 Oct 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Effect of Cyclopiazonic Acid on the Force-Frequency Relationship in Human Nonfailing  Myocardium
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherCARDIOVASCULAR PHARMACOLOGY

Effect of Cyclopiazonic Acid on the Force-Frequency Relationship in Human Nonfailing  Myocardium

Robert H. G. Schwinger, Klara Brixius, Udo Bavendiek, Susanne Hoischen, Jochen Müller-Ehmsen, Birgit Bölck and Erland Erdmann
Journal of Pharmacology and Experimental Therapeutics October 1, 1997, 283 (1) 286-292;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherCARDIOVASCULAR PHARMACOLOGY

Effect of Cyclopiazonic Acid on the Force-Frequency Relationship in Human Nonfailing  Myocardium

Robert H. G. Schwinger, Klara Brixius, Udo Bavendiek, Susanne Hoischen, Jochen Müller-Ehmsen, Birgit Bölck and Erland Erdmann
Journal of Pharmacology and Experimental Therapeutics October 1, 1997, 283 (1) 286-292;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Preconditioning of Rat Heart with Monophosphoryl Lipid A: A Role for Nitric Oxide
  • TAS-301, an Inhibitor of Smooth Muscle Cell Migration and Proliferation, Inhibits Intimal Thickening after Balloon Injury to Rat Carotid Arteries
  • Identification of Low Molecular Weight GP IIb/IIIa Antagonists That Bind Preferentially to Activated Platelets
Show more CARDIOVASCULAR PHARMACOLOGY

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics